DIAGNOSING, TREATING, AND MANAGING SCLERITIS IN 2020 AN EXPERT PANEL RECOMMENDATION PANEL MEMBERS MELISSA TOYOS, MD STEPHEN D. ANESI, MD, FACS n Partner and Director of Research n Massachusetts Eye Research & Surgery Institution n Toyos Clinic n Waltham, MA n Nashville, TN DAVID S. CHU, MD n Medical Director, Metropolitan Eye Research THOMAS A. ALBINI, MD & Surgery Institute n Professor of Clinical Ophthalmology n Associate Professor of Clinical Ophthalmology n University of Miami Health n Rutgers University n Bascom Palmer Eye Institute n Newark, NJ n Miami, FL ROBERT C. WANG, MD n Texas Retina Associates n Dallas, TX Corresponding Author: Melissa Toyos, MD; Toyos Clinic, Nashville, TN;
[email protected]. This work was supported by an unrestricted medical writing grant from Mallinckrodt Pharmaceuticals and is based on a virtual roundtable discussion hosted by Evolve Medical Education LLC. Although uncommon, scleritis is a dangerous immune-me- DIAGNOSING SCLERITIS diated disease that can potentially threaten the structural Melissa Toyos, MD: What percentage of patients in integrity of the eye and may be indicative of potentially your practice have scleritis? life-threatening systemic vasculitis.1,2 Data on the genetic factors of scleritis is lacking, but it is thought that genes affect- Stephen D. Anesi, MD, FACS: Scleritis accounts for 10% ing systemic autoimmune diseases impact scleritis as well.2 to 15% of the patients I see in my practice. Differentiating between episcleritis and scleritis and posterior and anterior scleritis can be challenging for physicians. An David S. Chu, MD: I agree; 10% to 15% sounds right to accurate diagnosis is critical to properly treat the disease and me as well.